News

Aptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the [...]

Aptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are [...]

Aptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe [...]

Aptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as [...]

Aptahem (publ) announced today that manufacture of its drug product has been delayed as a result of technical challenges. As a consequence, Aptahem anticipates that commencement of the planned [...]

Aptahem AB (publ) today announces that the company intends to recall the outstanding amount of convertible notes held by YA II PN Ltd, a fund represented by the U.S.-based Yorkville Advisors [...]

In the fight to save a person affected by sepsis every second counts – each hour that passes increases the risk of death with 8 percent. It is literally a race against time, a race that the [...]

Aptahem (publ) announce today that the extended exploratory sepsis study in primates has shown positive results. This increases the hope of being able to show good efficacy also in upcoming and [...]

Aptahem (publ) announce today that the final reports from the non-regulated GLP (Good Laboratory Practice) toxicology- and safety studies in Apta-1’s pre-clinical program show positive results. [...]

On 26 June 2018, Aptahem (publ) signed an issuance agreement with YA II PN Ltd, a fund represented by the United States-based Yorkville Advisors Global (“Yorkville”), which describes [...]